Compass Therapeutics reports CTX-009 Phase 1 data: 19% ORR at RP2D in heavily pre-treated tumors

Compass Therapeutics, Inc.

CTX-009 monotherapy achieved 19% ORR (3/16) at RP2D (10.0-12.5 mg/kg) and 69% DCR.
Across all doses, ORR was 8% (4 partial responses) and DCR was 62% in heavily pre-treated patients (median 3 prior lines).
Treatment well tolerated; no dose-limiting toxicities; hypertension in 38% (17/45), 7 Grade 3.
94% of colorectal and 58% of gastric patients had prior anti-VEGF therapy (bevacizumab/ramucirumab).
Phase 1b combo and Phase 2 studies underway; Compass holds global rights except S. Korea and China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.